A Review of Romiplostim Mechanism of Action and Clinical Applicability
Authors:
Open Access
- 1 May 2021
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 15, 2243-2268
Abstract
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune disease, bone marrow disorders, pathologic conditions associated with surgical procedures, hematopoietic stem cell transplant (HSCT), and hematologic disorders associated with severe aplastic anemia. Immune thrombocytopenia (ITP) is caused by immune reactions that accelerate destruction and reduce production of platelets. Thrombopoietin (TPO) is a critical component of platelet production pathways, and TPO receptor agonists (TPO-RAs) are important for the management of ITP by increasing platelet production and reducing the need for other treatments. Romiplostim is a TPO-RA approved for use in patients with ITP in the United States, European Union, Australia, and several countries in Africa and Asia, as well as for use in patients with refractory aplastic anemia in Japan and Korea. Romiplostim binds to and activates the TPO receptor on megakaryocyte precursors, thus promoting cell proliferation and viability, resulting in increased platelet production. Through this mechanism, romiplostim reduces the need for other treatments and decreases bleeding events in patients with thrombocytopenia. In addition to its efficacy in ITP, studies have shown that romiplostim is effective in improving platelet counts in various settings, thereby highlighting the versatility of romiplostim. The efficacy of romiplostim in such disorders is currently under investigation. Here, we review the structure, mechanism, pharmacokinetics, and pharmacodynamics of romiplostim. We also summarize the clinical evidence supporting its use in ITP and other disorders that involve thrombocytopenia, including chemotherapy-induced thrombocytopenia, aplastic anemia, acute radiation syndrome, perisurgical thrombocytopenia, post-HSCT thrombocytopenia, and liver disease.Keywords
This publication has 183 references indexed in Scilit:
- The serum levels of the cytokines involved in the Th17 and Th1 cell commitment are increased in individuals with borderline thrombocytopeniaJournal of Hematology & Oncology, 2013
- High Doses of Romiplostim Induce Proliferation and Reduce Proplatelet Formation by Human MegakaryocytesPLOS ONE, 2013
- Interleukin-6 signalling: More than Jaks and STATsEuropean Journal of Cell Biology, 2012
- The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopeniaHaematologica, 2011
- Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agentsBlood, 2010
- Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy SubjectsThe AAPS Journal, 2010
- Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor AgonistStem Cells, 2009
- T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpuraNature Medicine, 2003
- Mechanisms of Response to Treatment in Autoimmune Thrombocytopenic PurpuraNew England Journal of Medicine, 1989
- An Antibody Cytotoxic to Megakaryocyte Progenitor Cells in a Patient with Immune Thrombocytopenic PurpuraNew England Journal of Medicine, 1985